Table 3 Treatment status of nintedanib switched from pirfenidone
|  | (n = 30) |
|---|---|
Administration period of nintedanib (months) | 5.30 [2.84, 11.8] |
Discontinued | 18 (60.0%) |
 Discontinued within 6 months | 16 (53.3%) |
 Reason for discontinuation | |
  Liver injury | 3 (10.0%) |
  Anorexia + weight loss | 3 (10.0%) |
  Deterioration of physical condition | 3 (10.0%) |
  Death | 3 (10.0%) |
  Acute exacerbation of IPF | 3 (10.0%) |
  Diarrhea | 1 (3.3%) |
  Nausea | 1 (3.3%) |
  Rash | 1 (3.3%) |
Continued | 12 (40.0%) |
 Continued without interruption/dose reduction | 7 (23.3%) |
 Need at least ≥1 interruption and/or dose reduction | 5 (16.7%) |
 Reason for interruption and/or dose reduction | |
  Liver injury | 2 (6.7%) |
  Diarrhea | 2 (6.7%) |
  Fever | 1 (3.3%) |